Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients 18 years of age or older currently being treated with an ACE-I or ARB and with one of the following conditions:~1. Non-nephrotic range proteinuria (between 1 and 3 grams/day by 24-hr collection), hypertension (blood pressure \>130/80 or current use of antihypertensive drug therapy), and an eGFR of less than or equal to 40 ml/minute but greater than 20 ml/minute.~   OR~2. Nephrotic range proteinuria (\>=3 grams/day proteinuria) by 24-hr urine collection, and an eGFR greater than 20 ml/minute~Exclusion Criteria:~1. Acute renal failure: defined by \>25% decrease in eGFR over one month~2. Pregnancy or currently breast-feeding~3. Current use of cytotoxic drug therapy (cyclophosphamide, cyclosporine, mycophenolate mofetil, prednisone, chlorambucil) or a current indication for, and plan to implement, such therapy.~4. Current use of PTF~5. Contraindication to use of PTF drug: history of PTF or theophylline allergy, history of severe retinal hemorrhage or recent cerebral hemorrhage~6. Current use of theophylline~7. Contraindication to ACE-I or ARB.~8. Fewer than 2 measured serum creatinine values separated by 6 months prior to potential enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pentoxifylline (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).